Controlled-release PTH compound

US11890326B2 · kind B2 · utility

Assignee

• ASCENDIS PHARMA BONE DISEASES A/S · DK

Inventors

• Kennett Sprogøe · Rudegård, DK
• Felix Cleemann · Mainz, DE
• Guillaume Maitro · Mannheim, DE
• Mathias Krusch · Hirschhorn, DE
• Thomas Wegge · Heidelberg, DE
• Joachim Zettler · Heidelberg, DE

Key dates

• Filing date: Dec 8, 2022
• Grant date: Feb 6, 2024
• Expiry date: Dec 8, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K47/34
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a controlled-release parathyroid hormone (PTH) compound in which PTH(1-34) is reversibly conjugated to a branched polyethylene glycol. The invention further relates to a pharmaceutical composition of the compound. The compound or pharmaceutical composition is useful for treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH.